Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term - TCTMD
4/3/2022 12:00:00 AM3 years 1 month ago
by Shelley Wood
by Shelley Wood
An interim look at the EXPLORER-LTE study showed no safety signals but sustained benefits in LVOT and LVEF improvements.
WASHINGTON, DCMavacamten continues to deliver benefits in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) beyond 48 weeks, according to interim results from the ongoing EXPLOR… [+6934 chars]
full article...